This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/bindingdb/
n24http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/drugbank/
n21http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n11http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00104/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00104
rdf:type
n3:Drug
n3:description
Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.
n3:dosage
n19:271B4578-363D-11E5-9242-09173F13E4C5 n19:271B4579-363D-11E5-9242-09173F13E4C5 n19:271B457A-363D-11E5-9242-09173F13E4C5 n19:271B457B-363D-11E5-9242-09173F13E4C5 n19:271B457C-363D-11E5-9242-09173F13E4C5 n19:271B457D-363D-11E5-9242-09173F13E4C5 n19:271B4570-363D-11E5-9242-09173F13E4C5 n19:271B4571-363D-11E5-9242-09173F13E4C5 n19:271B4572-363D-11E5-9242-09173F13E4C5 n19:271B4573-363D-11E5-9242-09173F13E4C5 n19:271B4574-363D-11E5-9242-09173F13E4C5 n19:271B4575-363D-11E5-9242-09173F13E4C5 n19:271B4576-363D-11E5-9242-09173F13E4C5 n19:271B4577-363D-11E5-9242-09173F13E4C5 n19:271B456C-363D-11E5-9242-09173F13E4C5 n19:271B456D-363D-11E5-9242-09173F13E4C5 n19:271B456E-363D-11E5-9242-09173F13E4C5 n19:271B456F-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Uhl W, Anghelacopoulos SE, Friess H, Buchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion. 1999;60 Suppl 2:23-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10207228
n3:group
approved investigational
n3:indication
For treatment of acromegaly and reduction of side effects from cancer chemotherapy
n3:manufacturer
n8:271B455E-363D-11E5-9242-09173F13E4C5 n8:271B455C-363D-11E5-9242-09173F13E4C5 n8:271B455D-363D-11E5-9242-09173F13E4C5 n8:271B455A-363D-11E5-9242-09173F13E4C5 n8:271B455B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00104 n28:DB00104
dcterms:title
Octreotide
adms:identifier
n7:Octreotide n9:PA450678 n12:D00442 n13:0078-0180-01 n14:C07306 n15:50175592 n16:DB00104
n3:mechanismOfAction
Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
n3:packager
n8:271B4550-363D-11E5-9242-09173F13E4C5 n8:271B4551-363D-11E5-9242-09173F13E4C5 n8:271B454F-363D-11E5-9242-09173F13E4C5 n8:271B4554-363D-11E5-9242-09173F13E4C5 n8:271B4555-363D-11E5-9242-09173F13E4C5 n8:271B4552-363D-11E5-9242-09173F13E4C5 n8:271B4553-363D-11E5-9242-09173F13E4C5 n8:271B4558-363D-11E5-9242-09173F13E4C5 n8:271B4559-363D-11E5-9242-09173F13E4C5 n8:271B4556-363D-11E5-9242-09173F13E4C5 n8:271B4557-363D-11E5-9242-09173F13E4C5
n3:patent
n23:1328402 n23:5922338 n23:5538739
n3:routeOfElimination
About 32% of the dose is excreted unchanged into the urine.
n3:synonym
Octrotide Octreotidum Octreotida
n3:volumeOfDistribution
* 13.6 L [healthy volunteers] * 21.6±8.5 L [patients with acromegaly]
n17:hasAHFSCode
n24:92-00-00
n3:salt
n3:synthesisReference
Nishith Chaturvedi, "Novel process for production of the somatostatin analog, octreotide." U.S. Patent US20040225108, issued November 11, 2004.
n26:hasConcept
n27:M0023526
foaf:page
n11:octreotide.htm n22:octreotide.html
n3:IUPAC-Name
n5:271B4582-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4588-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4587-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4584-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4585-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4586-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4580-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4598-363D-11E5-9242-09173F13E4C5 n5:271B4581-363D-11E5-9242-09173F13E4C5 n5:271B457E-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B457F-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:H01CB02
n3:H-Bond-Acceptor-Count
n5:271B458E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B458F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4589-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B458A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B458C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B458B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B458D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
83150-76-9
n3:category
n3:clearance
* 7 – 10 L/hr [healthy after 100-mcg SC injection] * 18 L/hr [patients with acromegaly after 100-mcg SC injection] * 8.8 L/hr [mild renal impairment after 100-mcg SC injection] * 7.3 L/hr [moderate renal impairment after 100-mcg SC injection] * 7.6 L/hr [severe renal impairment after 100-mcg SC injection] * 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection] * 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection] * 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]
n3:containedIn
n4:271B4561-363D-11E5-9242-09173F13E4C5 n4:271B4564-363D-11E5-9242-09173F13E4C5 n4:271B455F-363D-11E5-9242-09173F13E4C5 n4:271B4565-363D-11E5-9242-09173F13E4C5 n4:271B4562-363D-11E5-9242-09173F13E4C5 n4:271B4563-363D-11E5-9242-09173F13E4C5 n4:271B4568-363D-11E5-9242-09173F13E4C5 n4:271B4569-363D-11E5-9242-09173F13E4C5 n4:271B4566-363D-11E5-9242-09173F13E4C5 n4:271B4567-363D-11E5-9242-09173F13E4C5 n4:271B456A-363D-11E5-9242-09173F13E4C5 n4:271B456B-363D-11E5-9242-09173F13E4C5 n4:271B4560-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4594-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4596-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4597-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4593-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4592-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4595-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4583-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4590-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4591-363D-11E5-9242-09173F13E4C5